{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:38:29Z","timestamp":1794555509497,"version":"4.9.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejpb.2024.114346","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T07:20:03Z","timestamp":1717140003000},"page":"114346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Formulation development of tazarotene-loaded PLGA nanoparticles for follicular delivery in the treatment of inflammatory skin diseases"],"prefix":"10.1016","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9461-5668","authenticated-orcid":false,"given":"Sharvari M.","family":"Kshirsagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kipping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4005-5359","authenticated-orcid":false,"given":"Ajay K.","family":"Banga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2020","key":"10.1016\/j.ejpb.2024.114346_b0005","first-page":"566","article-title":"Global burden of psoriasis \u2013 comparison of regional and global epidemiology, to 2017","volume":"59","author":"AlQassimi","year":"1990","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.ejpb.2024.114346_b0010","doi-asserted-by":"crossref","unstructured":"H. Chen, T.C. Zhang, X. Yin, J. Man, M. Lu, Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019, Br. J. Dermatol. 186 (2022) 673\u2013683. DOI: 10.1111\/bjd.20882.","DOI":"10.1111\/bjd.20882"},{"key":"10.1016\/j.ejpb.2024.114346_b0015","article-title":"Acne vulgaris A review of causes and treatment options","volume":"38","author":"Danielle Well","year":"2013","journal-title":"Nurse Pract."},{"key":"10.1016\/j.ejpb.2024.114346_b0020","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.ejpb.2024.114346_b0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00128071-200304030-00006","article-title":"Optimizing treatment with topical tazarotene","volume":"4","author":"Guenther","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.ejpb.2024.114346_b0030","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0190-9622(97)80395-7","article-title":"Tazarotene: The first receptor-selective topical retinoid for the treatment of psoriasis","volume":"37","author":"Chandraratna","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejpb.2024.114346_b0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/ciia.2006.1.4.327","article-title":"Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety","author":"Mukherjee","year":"2006","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.ejpb.2024.114346_b0040","first-page":"1280","article-title":"Tazarotene revisited: safety and efficacy in plaque psoriasis and its emerging role in treatment strategy","volume":"17","author":"Tanghetti","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.ejpb.2024.114346_b0045","unstructured":"FDA, TAZORAC \u00ae (tazarotene) Gel, 0.05% (tazarotene) Gel, 0.1% (Reference ID: 4127830), 2017."},{"key":"10.1016\/j.ejpb.2024.114346_b0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/17425247.5.2.235","article-title":"Drug delivery and formulations for the topical treatment of psoriasis","volume":"5","author":"Su","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114346_b0055","unstructured":"FDA, TAZORAC\u00ae (tazarotene) cream, 0.05% and 0.1%, for topical use (Reference ID: 3420370), 2013. www.fda.gov\/medwatch."},{"key":"10.1016\/j.ejpb.2024.114346_b0060","unstructured":"National Library of Medicine, PubChem- Tazarotene, (2024). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/tazarotene (accessed February 19, 2024)."},{"key":"10.1016\/j.ejpb.2024.114346_b0065","first-page":"82","article-title":"Liposomal gels as carriers for safer topical delivery of tazarotene","volume":"3","author":"Makky","year":"2013","journal-title":"J. Pharm. Res. Opin."},{"key":"10.1016\/j.ejpb.2024.114346_b0070","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3109\/03639045.2015.1062512","article-title":"Optimizing the dermal accumulation of a tazarotene microemulsion using skin deposition modeling","volume":"42","author":"Nasr","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2024.114346_b0075","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msec.2017.05.036","article-title":"Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis","volume":"79","author":"Prasad","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ejpb.2024.114346_b0080","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/10667857.2021.1873637","article-title":"Design and development of solid lipid nanoparticles of tazarotene for the treatment of psoriasis and acne: a quality by design approach","volume":"37","author":"Sharma","year":"2022","journal-title":"Mater. Technol."},{"key":"10.1016\/j.ejpb.2024.114346_b0085","unstructured":"I. Bausch Health Americas, A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (ID:NCT03168334), ClinicalTrials.Gov (2021). https:\/\/clinicaltrials.gov\/study\/NCT03168334#study-overview (accessed February 21, 2024)."},{"key":"10.1016\/j.ejpb.2024.114346_b0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/17425247.2020.1700226","article-title":"Recent advances in follicular drug delivery of nanoparticles","volume":"17","author":"Patzelt","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114346_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121273","article-title":"Mapping hair follicle-targeted delivery by particle systems: What has science accomplished so far?","volume":"610","author":"Costa","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114346_b0100","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-018-2369-6","article-title":"Delivery of methotrexate and characterization of skin treated by fabricated PLGA microneedles and fractional ablative laser","volume":"35","author":"Nguyen","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114346_b0105","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/10837450.2013.778874","article-title":"Polymeric microparticles-based formulation for the eradication of cutaneous candidiasis: Development and characterization","volume":"19","author":"Kumar","year":"2014","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2024.114346_b0110","doi-asserted-by":"crossref","DOI":"10.1007\/s40204-017-0063-0","article-title":"Poly(lactic-co-glycolic) acid drug delivery systems through transdermal pathway: an overview","volume":"6","author":"Naves","year":"2017","journal-title":"Prog. Biomater."},{"key":"10.1016\/j.ejpb.2024.114346_b0115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijpharm.2017.09.054","article-title":"Technical aspects of preparing PEG-PLGA nanoparticles as carrier for chemotherapeutic agents by nanoprecipitation method","volume":"533","author":"Almoustafa","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114346_b0120","first-page":"264","article-title":"Differential stripping: determination of the amount of topically applied substances penetrated into the hair follicles, journal of investigational","volume":"125","author":"Teichmann","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.ejpb.2024.114346_b0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","article-title":"DDSolver: An add-in program for modeling and comparison of drug dissolution profiles","volume":"12","author":"Zhang","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2024.114346_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123547","article-title":"Microneedle-mediated transdermal delivery of N-acetyl cysteine as a potential antidote for lewisite injury","volume":"647","author":"Kshirsagar","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114346_b0135","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s11095-022-03406-8","article-title":"Fabrication of polymeric microneedles using novel vacuum compression molding technique for transdermal drug delivery","volume":"39","author":"Kshirsagar","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114346_b0140","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-023-02527-6","article-title":"Enhanced transdermal delivery of N-acetylcysteine and 4-phenylbutyric acid for potential use as antidotes to lewisite","volume":"24","author":"Dandekar","year":"2023","journal-title":"AAPS PharmSci Tech"},{"key":"10.1016\/j.ejpb.2024.114346_b0145","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/17425247.2022.2135700","article-title":"Development and evaluation of a drug-in-adhesive transdermal delivery system for delivery of olanzapine","volume":"19","author":"Vora","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114346_b0150","first-page":"1048","article-title":"Development and evaluation of transdermal delivery system of tranylcypromine for the treatment of depression, Drug Deliv","volume":"13","author":"Shrestha","year":"2022","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejpb.2024.114346_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123992","article-title":"Comparative evaluation of physical and chemical enhancement techniques for transdermal delivery of linagliptin","volume":"654","author":"Karve","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114346_b0160","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/jps.23627","article-title":"Adapalene microemulsion for transfollicular drug delivery","volume":"102","author":"Bhatia","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114346_b0165","unstructured":"M. Manian, Formulation and evaluation of dermatological products For topical delivery, Mercer University College of Pharmacy, 2016."},{"key":"10.1016\/j.ejpb.2024.114346_b0170","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/10837450.2020.1765180","article-title":"Tazarotene-loaded in situ gels for potential management of psoriasis: biocompatibility, anti-inflammatory and analgesic effect","volume":"25","author":"Erol","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2024.114346_b0175","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10837450.2015.1081610","article-title":"Novel microemulsion-based gel formulation of tazarotene for therapy of acne","volume":"21","author":"Patel","year":"2016","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2024.114346_b0180","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/2211738504666160804154213","article-title":"Pharmaceutical Nanotechnology BENTHAM SCIENCE Send Orders for Reprints to reprints@benthamscience.ae development and comparison of nanosponge and niosome based gel for the topical delivery of tazarotene","volume":"4","author":"Aggarwal","year":"2016","journal-title":"Pharm Nanotechnol"},{"key":"10.1016\/j.ejpb.2024.114346_b0185","first-page":"37","article-title":"Formulation and evaluation of ethosomal gel of tazarotene for topical delivery","volume":"13","author":"Thomas","year":"2019","journal-title":"Asian J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114346_b0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15655-z","article-title":"Microsponge based gel as a simple and valuable strategy for formulating and releasing Tazarotene in a controlled manner","volume":"12","author":"Khattab","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2024.114346_b0195","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0168-3659(02)00211-0","article-title":"Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics","volume":"83","author":"Chorny","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114346_b0200","first-page":"237","article-title":"In vitro degradation and erosion behavior of commercial PLGAs used for controlled drug delivery, Drug Deliv","volume":"13","author":"Walker","year":"2023","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejpb.2024.114346_b0205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2007.01.016","article-title":"Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo","volume":"119","author":"Mittal","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114346_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040870","article-title":"Effect of solvents, stabilizers and the concentration of stabilizers on the physical properties of Poly(D, L-lactide-co-glycolide) nanoparticles: encapsulation, in vitro release of indomethacin and cytotoxicity against HepG2-Cell","volume":"14","author":"Alkholief","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114346_b0215","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1080\/10717544.2021.1995078","article-title":"Formulation and evaluation of butenafine loaded PLGA-nanoparticulate laden chitosan nano gel","volume":"28","author":"Alshehri","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114346_b0220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijpharm.2017.08.064","article-title":"Nanoprecipitation process: From encapsulation to drug delivery","volume":"532","author":"Mart\u00ednez Rivas","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114346_b0225","doi-asserted-by":"crossref","unstructured":"A.K. Banga, Transdermal and intradermal delivery of therapeutic agents: application of physical technologies, CRC Press , 2011. DOI: DOI: 10.1201\/b10906.","DOI":"10.1201\/b10906"},{"key":"10.1016\/j.ejpb.2024.114346_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030680","article-title":"Formulation development for transdermal delivery of raloxifene, a chemoprophylactic agent against breast cancer","volume":"14","author":"Vora","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114346_b0235","first-page":"163","article-title":"Skin models for the testing of transdermal drugs","volume":"8","author":"Abd","year":"2016","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2024.114346_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04663","article-title":"Recent advances in topical carriers of anti-fungal agents","volume":"6","author":"Garg","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.ejpb.2024.114346_b0245","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejpb.2006.10.019","article-title":"Nanoparticles - An efficient carrier for drug delivery into the hair follicles","volume":"66","author":"Lademann","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114346_b0250","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1002\/jps.23282","article-title":"Surface-charge-dependent nanoparticles accumulation in inflamed skin","volume":"101","author":"Abdel-Mottaleb","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114346_b0255","article-title":"Transdermal drug delivery of tazarotene: determining tazarotene\u2019s potential in local transdermal therapy","volume":"16","author":"Hamzehpour","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114346_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/pr7120871","article-title":"Application of an in vitro psoriatic skin model to study cutaneous metabolization of tazarotene","volume":"7","author":"Morin","year":"2019","journal-title":"Processes"},{"key":"10.1016\/j.ejpb.2024.114346_b0265","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4557","article-title":"Development of a simple method for simultaneous determination of tazarotene and betamethasone dipropionate and their metabolites using LC\u2013MS method and its application to dermatopharmacokinetic study","volume":"33","author":"Li","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejpb.2024.114346_b0270","first-page":"273","article-title":"Clinical pharmacokinetics and drug metabolism of tazarotene a novel topical treatment for acne and psoriasis","volume":"37","author":"Tang-Liu","year":"1999","journal-title":"Drug Disposition"},{"key":"10.1016\/j.ejpb.2024.114346_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e08938","article-title":"Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery","volume":"8","author":"Souto","year":"2022","journal-title":"Heliyon"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124001723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124001723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T02:37:49Z","timestamp":1728009469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124001723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":55,"alternative-id":["S0939641124001723"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114346","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation development of tazarotene-loaded PLGA nanoparticles for follicular delivery in the treatment of inflammatory skin diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114346"}}